IS7576A - And-mýelíntengd glýkóprótín (MAG) mótefni - Google Patents

And-mýelíntengd glýkóprótín (MAG) mótefni

Info

Publication number
IS7576A
IS7576A IS7576A IS7576A IS7576A IS 7576 A IS7576 A IS 7576A IS 7576 A IS7576 A IS 7576A IS 7576 A IS7576 A IS 7576A IS 7576 A IS7576 A IS 7576A
Authority
IS
Iceland
Prior art keywords
myelin
mag
antibodies
linked glycoprotein
glycoprotein
Prior art date
Application number
IS7576A
Other languages
English (en)
Inventor
Henry Ellis Jonathan
Germaschewski Volker
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7576A publication Critical patent/IS7576A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7576A 2002-08-06 2004-11-30 And-mýelíntengd glýkóprótín (MAG) mótefni IS7576A (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
PCT/EP2003/008749 WO2004014953A2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies

Publications (1)

Publication Number Publication Date
IS7576A true IS7576A (is) 2004-11-30

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7576A IS7576A (is) 2002-08-06 2004-11-30 And-mýelíntengd glýkóprótín (MAG) mótefni

Country Status (23)

Country Link
US (2) US7612183B2 (is)
EP (1) EP1526868B1 (is)
JP (1) JP4528121B2 (is)
KR (1) KR101078459B1 (is)
CN (1) CN100542607C (is)
AR (1) AR040778A1 (is)
AU (1) AU2003255390B2 (is)
BR (1) BR0312456A (is)
CA (1) CA2494008C (is)
CY (1) CY1114919T1 (is)
DK (1) DK1526868T3 (is)
ES (1) ES2440652T3 (is)
IL (1) IL165478A (is)
IS (1) IS7576A (is)
MX (1) MXPA05001468A (is)
MY (1) MY148409A (is)
NO (1) NO333876B1 (is)
NZ (1) NZ537123A (is)
PL (1) PL211014B1 (is)
PT (1) PT1526868E (is)
SI (1) SI1526868T1 (is)
TW (1) TWI323265B (is)
WO (1) WO2004014953A2 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981420B2 (en) 2000-12-22 2011-07-19 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
ES2542501T3 (es) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
CN107929731A (zh) 2005-11-04 2018-04-20 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
JP2009536641A (ja) * 2006-05-31 2009-10-15 ハンワ ケミカル コーポレイション Ｖｃａｍ−１特異的モノクローナル抗体
RU2474589C9 (ru) 2006-11-02 2019-08-15 Дженентек, Инк. Гуманизированные антитела к фактору d и их применения
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20110015604A (ko) 2008-05-06 2011-02-16 글락소 그룹 리미티드 생물학적 활성제의 캡슐화
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8383778B2 (en) * 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
DK2510001T3 (en) 2009-12-08 2016-02-29 Abbvie Deutschland MONOCLONAL ANTIBODIES AGAINST RGM A PROTEIN USED TO TREAT DEGENERATION OF THE RETINAL NERVE FIBER LAYER
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
EP2579895A4 (en) * 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
MX352772B (es) 2012-01-27 2017-12-07 Abbvie Deutschland Composición y método para el diagnóstico y tratamiento de enfermedades asociadas con la degeneración de neuritas.
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
HK1223980A1 (zh) 2013-12-20 2017-08-11 F. Hoffmann-La Roche Ag 改进的重组多肽生产方法
RU2760005C2 (ru) 2014-03-13 2021-11-22 Университет Базель УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА
MA39934A (fr) 2014-05-01 2017-03-08 Hoffmann La Roche Variants d'anticorps anti-facteur d et leurs utilisations
CN107810199B (zh) 2015-06-24 2021-11-09 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
JP6843868B2 (ja) 2015-09-29 2021-03-17 セルジーン コーポレイション Ｐｄ−１結合タンパク質及びその使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114057884A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
CA3036701A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
DE122006000043I1 (de) * 1994-01-25 2007-02-15 Elan Pharm Inc Humanisierte Antik¦rper gegen das Leukozytenadh{sionsmolek}l vla-4
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
JPH11504211A (ja) 1995-04-19 1999-04-20 アコルダ セラピューティクス 中枢神経系ニューライトの成長調節因子並びに構成物、細胞及びそれを具体化し使用する方法
DE69633336T2 (de) * 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
AU724856B2 (en) * 1995-06-30 2000-10-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US5962434A (en) 1995-08-25 1999-10-05 The Johns Hopkins University School Of Medicine Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US20030017147A1 (en) 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
IL135799A0 (en) * 1997-10-28 2001-05-20 Univ British Columbia Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
JP2001526021A (ja) 1997-11-14 2001-12-18 ユーロ−セルティーク，エス．エイ． 合成の可変領域と改変された特異性を有する免疫グロブリン分子
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
ATE483021T1 (de) 1998-07-22 2010-10-15 Smithkline Beecham Ltd Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns
AU771239C (en) * 1998-09-14 2004-10-14 Soren Buus A method of producing a functional immunoglobulin superfamily protein
CN1354755B (zh) 1998-11-06 2010-06-02 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
JP2002535289A (ja) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
AU2001234125A1 (en) * 2000-02-22 2001-09-03 Medical And Biological Laboratories Co., Ltd. Antibody library
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
TW200403254A (en) 2004-03-01
PL211014B1 (pl) 2012-03-30
JP4528121B2 (ja) 2010-08-18
EP1526868A2 (en) 2005-05-04
EP1526868B1 (en) 2013-10-23
NO333876B1 (no) 2013-10-07
AR040778A1 (es) 2005-04-20
CY1114919T1 (el) 2016-12-14
CA2494008C (en) 2012-12-11
US20090053214A1 (en) 2009-02-26
WO2004014953A3 (en) 2004-05-06
US7612183B2 (en) 2009-11-03
HK1077206A1 (en) 2006-02-10
CA2494008A1 (en) 2004-02-19
US20060165681A1 (en) 2006-07-27
NZ537123A (en) 2007-05-31
SI1526868T1 (sl) 2014-01-31
AU2003255390A1 (en) 2004-02-25
NO20045323L (no) 2005-02-10
KR101078459B1 (ko) 2011-10-31
BR0312456A (pt) 2005-04-19
US8071731B2 (en) 2011-12-06
IL165478A (en) 2010-12-30
MXPA05001468A (es) 2005-06-06
PL375405A1 (en) 2005-11-28
CN100542607C (zh) 2009-09-23
TWI323265B (en) 2010-04-11
MY148409A (en) 2013-04-30
PT1526868E (pt) 2014-01-07
WO2004014953A2 (en) 2004-02-19
AU2003255390B2 (en) 2011-02-03
CN1671417A (zh) 2005-09-21
ES2440652T3 (es) 2014-01-29
KR20050049470A (ko) 2005-05-25
JP2006512899A (ja) 2006-04-20
DK1526868T3 (da) 2014-01-13

Similar Documents

Publication Publication Date Title
IS7576A (is) And-mýelíntengd glýkóprótín (MAG) mótefni
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
NO20044347L (no) Anti-alfavbeta6-antistoff
NO20044326D0 (no) Virale antigener
IS6982A (is) Mótefni gegn VLA-1
FI4933U1 (fi) Satulatuoli
NO20044327L (no) Konsentrerte suspensjoner
DE60322453D1 (de) System zum Bereitstellen von Diensten
NO20044046L (no) Substituerte hydroksyetylaminer
NO20034452L (no) Sykdoms-assosiert protein
EE200300569A (et) CD44v6-spetsiifilised antikehad
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE60328033D1 (de) Cannabinoid-rezeptorliganden
NO20016259D0 (no) Trosse
EP1359932A4 (en) TIP39 POLYPEPTIDES
NO20044145L (no) Assay for anti-INGAP antistoffer
FI20011055L (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
ATA9342002A (de) Sortieranlage
DE10391559D2 (de) Gerüst
ATE350379T1 (de) Substituierte benzdioxepine
NO20053512D0 (no) IL-8-liknende proteiner
NO20050436D0 (no) Beta-lagnedbrytende peptider
DE10241760B8 (de) Fackel
DK1494693T3 (da) Cripto-specifikke antistoffer
NO20052608D0 (no) Midkinlignende protein